Sign up
Pharma Capital

LeanLife Health taps Chris Nichols as operations advisor

Nichols formerly managed dozens of capital projects from design through to completion and boasts of experience with Coca Cola and Molson Coors
omega 3 gel caps
Lean Life Health develops omega-3 products which can be formulated as liquids, emulsions or powders and used as food additives

LeanLife Health Inc (CSE:LLP) announced Wednesday that it has hired Chris Nichols as operations advisor to consult on the design of the company’s production facility.

Nichols, who will assist the new operations manager Glenn Nichols, boasts over 25 years of operations experience with companies such as Coca Cola and Molson Coors.

READ: LeanLife Health continues in-house testing of its omega-3 products, reprices warrants

Using Six Sigma tools and training, Nichols specialized in process improvement and optimization in his previous positions, leveraging the moves into multiple millions of annualized cost savings. Nichols, who holds a science degree from Simon Fraser University, formerly managed dozens of capital projects from design through to completion. 

Headquartered in Vancouver, Lean Life Health develops omega-3 products which can be formulated as liquids, emulsions or powders and used as food additives. The long-lasting shelf life of the flaxseed oil produced by LeanLife's patented method makes it an ideal fortified food ingredient. It has been used to make bread, noodles, cheese, yogurt, juice and milk products for the European market.

READ: LeanLife Health bolsters team with new operations manager

The global Omega-3 market hit US$33 billion in 2016 and is expected to reach more than $57 billion by 2025, according to a report by Grand View research. Studies have since shown that Omega-3 fatty acids keep nerve cells functioning at optimal speed.

LeanLife shares held steady at C$0.04 in morning trade on Wednesday.

Contact Ellen Kelleher at [email protected]

View full LLP profile View Profile
Newswire

LeanLife issues stock options

View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.